Participated in Hepta Bio's $6.7M seed round for liquid biopsy-based AI diagnostics for chronic liver disease.
Hepta Bio builds a liquid biopsy-native AI platform that reads epigenetic patterns in cell-free DNA from blood to reveal liver biology
Hepta Bio builds a liquid biopsy-native AI platform that reads epigenetic patterns in cell-free DNA from blood to reveal liver biology. It is starting with non-invasive detection of MASH and is designed for routine clinical care.